Finerenone ' s Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD Finerenone ' s Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD

The nonsteroidal mineralocorticoid receptor antagonist showed cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease, with or without CVD, a phase 3 trial shows.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news